% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • stocktipster stocktipster Jun 23, 2012 10:05 AM Flag

    $12.00 In Twelve Months


    Twelve month run-up to the Afrezza approval in conjunction with a "big pharma" marketing partnership for Afrezza, another development partnership for one of the cancer drugs, and several Technosphere license agreements with other drug companies moves the share price to the $12.00 range or higher within a year.

    Check the one year chart on MDVN.

    The annual market for drugs to treat diabetes just in the United States will be over $55 billion dollar by the year 2020. The world wide market will be ten times that amount.

    Mannkind is currently substantially undervalued. is correct that Mannkind is due for a technical breakout. I suggest you buy a few shares before you miss the gap higher and the subsequent approval run.

    This topic is deleted.
2.08-0.11(-5.02%)Nov 27 1:00 PMEST